Home
    • Plans Blog Contact
    Corcept Therapeutics Incorporated logo

    Corcept Therapeutics Incorporated

    CORT
    Last price US$95.33
    Market cap US$9.6b
    12M price change 41.04%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Exelixis IncEXEL Industry peer United Therapeutics CorporationUTHR Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Corcept Therapeutics Incorporated Overview

    Industry: Biotechnology

    Sector: Healthcare

    Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia sec Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Corcept Therapeutics Incorporated into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 30, 2026

    Quarterly result summary

    Revenue was $164.9M (+5% YoY). Net loss was -$31.8M (from $20.5M).

    Revenue $164.9M +5% YoY
    Net loss -$31.8M from $20.5M

    What changed

    • Revenue +5% YoY to $164.9M.
    • Net loss was -$31.8M (from $20.5M).

    Guidance / outlook

    We expect results from our BELLA trial combining relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer by the end of this year, with results from our studies of relacorilant in patients with platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers available by the end of next year.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Apr 30, 2026 SEC filing 8-K Apr 30, 2026 Earnings release Earnings release Feb 24, 2026 SEC filing 10-K Feb 24, 2026 SEC filing 8-K Feb 24, 2026 SEC filing 8-K Nov 04, 2025 SEC filing 10-Q Nov 04, 2025 Earnings release Earnings release Nov 04, 2025 Earnings release Earnings release Jul 31, 2025 SEC filing 8-K Jul 31, 2025 SEC filing 10-Q Jul 31, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    Corcept Therapeutics Incorporated boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Exelixis Inc , United Therapeutics Corporation are companies with high ratings.

    Return on Equity

    Score 4.58/5
    Corcept Therapeutics Incorporated stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Corcept Ther... CORT US$9.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.94/5
    Corcept Therapeutics Incorporated commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Corcept Ther... CORT US$9.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Exelixis Inc , United Therapeutics Corporation are companies with high ratings.

    Leverage

    Score 3.72/5
    Corcept Therapeutics Incorporated attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Corcept Ther... CORT US$9.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Corcept Therapeutics Incorporated logo

    Corcept Therapeutics Incorporated

    US$95.33

    US$19.51

    -79.5% vs price

    US$9.6b

    5.15%

    41.04%